Customer No.: 31,834

Atty. Dkt. No. B-0497 PUS

## <u>REMARKS</u>

The Examiner has required restriction of the claims under 35 U.S.C. § 121. More specifically, the Examiner has required restriction to one of the following groups, as described

below:

RECEIVED **CENTRAL FAX CENTER** 

JAN 2 2 2008

Group 1	Claims 19 and 18-22 drawn to the special technical feature of a chemical conjugate between an immunoglobulin Fab fragment and molecular entities imparting diagnostic or therapeutic utility.
Group 2	Claims 10-16, drawn to the special technical feature of a process for the preparation of the conjugates of claim 1, comprising: a) the selective and quantitative reduction of the inter-chain disulfide bond of a Fab fragment to give two free sulfhydryl groups; b) the quantitative functionalization of one or both of the sulhydryl groups from step (a) with molecular entities having at least one free sulfhydryl group and imparting diagnostic or therapeutic utility, to give mono- or diconjugate compounds, said diconjugates deriving from either symmetric or asymmetric functionalization of the sulfhydryl groups.
Group 3	Claim 17, drawn to the special technical feature of N <sup>2</sup> ,N <sup>2</sup> -bis[2-[bis(carboxymethyl)amino]ethyl]-N <sup>6</sup> -[4-(2,5-dioxo-1 <i>H</i> -pyrrol-1-yl)-1-oxobutyl]-L-lysine as an intermediate compound for the preparation of conjugates og claim 1.

The Examiner has also required the election of a species for further examination.

## Elections

Applicants hereby elect the claims of Group 2 (claims 10-16). Applicants further elect the species of Example 4, in which the Fab fragment is the anti-Herpes simple virus of example 1, the conjugation moieties are compound D of Example 2,  $(N^2,N^2-bis[2-1])$ 

Customer No.: 31,834

Atty. Dkt. No. B-0497 PUS

[bis(carboxymethyl)amino]ethyl]-N<sup>6</sup>-[4-(2,5-dioxo-1H-pyrrol-1-yl)-1-oxobutyl]-L-lysine, the final compound is a di-conjugate, and the conditions used are those of pending claim 16.

Furthermore, Applicants identify claims 10-16 as encompassing the elected species.

No fee is believed to be necessary in connection with the filing of this Amendment and Response to Restriction Requirement. However, if any additional fee is necessary, applicant hereby authorizes such fee to be charged to Deposit Account No. <u>50-2168</u>.

Favorable action is respectfully requested.

Respectfully submitted,

Dated: January 21, 2008

M. Caragh Noone, Reg. No. 37,197

Bracco Research USA Inc.

305 College Road East

Princeton, NJ 08540

Tel: (609) 514-2454 Fax: (609) 514-2446